Navigation Links
Orexigen(R) Therapeutics Schedules March 9, 2010 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2009
Date:3/4/2010

SAN DIEGO, March 4 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce its fourth quarter and year ended December 31, 2009 financial results on Tuesday, March 9, 2010 before the markets open. The announcement will be followed by a live webcast and conference call at 8:00 a.m. Eastern time.

Orexigen management will host the call and webcast to discuss financial results and recent business highlights. The live call may be accessed by phone by calling (866) 730-5769 (domestic) or (857) 350-1593 (international), participant code 19470590. The webcast can be accessed live on the investor relations section of the Orexigen web site at www.orexigen.com and will be archived for 14 days following the call.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead investigational product, Contrave®, has completed Phase 3 clinical trials.  The Company's second product, Empatic™, has completed Phase 2 clinical development.  Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches.  Further information about the Company can be found at http://www.Orexigen.com.

SOURCE Orexigen Therapeutics, Inc.

Back to top

RELATED LINKS
http://www.Orexigen.com

'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen(R) Therapeutics Appoints Peter Honig, M.D. to Board of Directors
2. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
3. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
4. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
5. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
6. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
7. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
8. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
9. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
10. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
11. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)...  CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) ... Ph.D., as President and Chief Executive Officer (CEO) and member ... Craig succeeds Richard Love , interim President and CEO ... Directors.  Dr. Craig has over 20 years of experience in ... Europe . "On behalf of ...
(Date:2/24/2017)... -- Following receiving CE ... , s AMAR is a major milestone for the country ... w ound care market in Israel ... BST for inclusion in the National Health Basket , ...   E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for ...
(Date:2/24/2017)... DUBLIN , Feb 24, 2017 Research and ... Analysis and Strategies - 2016" report to their offering. ... The latest research Dry eye Drugs ... in the global Dry eye market. The research answers the following ... for Dry eye and their clinical attributes? How are they positioned in ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... 27, 2017 , ... It’s no secret that aging causes ... a host of health issues, including urinary incontinence. However, results published in late ... good overall muscle strength in older women, particularly in the abdominal and pelvic ...
(Date:2/27/2017)... ... ... The threat of nuclear warfare has long plagued this world. In July of ... of nuclear weapons. Years later, when her co-workers began dying, Dot started searching for ... Clayton exposes the critical decisions made by agencies involved in the nuclear testing during ...
(Date:2/27/2017)... POUGHKEEPSIE, N. Y. (PRWEB) , ... February 27, 2017 , ... ... Society ( ILADS ) has disclosed that despite scientific studies, the Center for Disease ... of chronic Lyme disease . Kenneth B. Liegner, M.D. has compiled into ...
(Date:2/27/2017)... ... February 27, 2017 , ... New Jersey ranks among the top five ... genders. And the need for advanced services is growing. , Project WE vs ... program, in collaboration with their non-profit partners in their fight against cancer and in ...
(Date:2/26/2017)... ... February 26, 2017 , ... LatitudeC Baby Products, ... today announced it would be offering some it’s exclusive product line to the ... quality and unique baby clothing/feeding products, will team up with AMAZON to distribute ...
Breaking Medicine News(10 mins):